Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreementReinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement. Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating Alvetex®Scaffold 3D cell culture technology
By: Reinnervate Under the terms of the partnership, Oncotest will offer its clients automated assays based on Alvetex®Scaffold technology, complementing their well known 3D Tumour Clonogenic Assay technology. Prof. Stefan Przyborski, founder and CSO of Reinnervate described the benefits of the 96 well plates for cancer cell cytotoxicity testing; ‘The Alvetex®Scaffold 96 well plate allows scientists to grow tumour cells in 3D, better mimicking the way these cells grow in vivo. It is very easy to start using 3D cell culture with Alvetex® technology. You simply seed the cells, add your existing media and place in your standard incubator. There is no struggling with new and sometimes cumbersome protocols required with other 3D technologies such as collagen gels or hanging drops’. He then went on to say; ‘We have shown that the Alvetex®Scaffold 96 well plates work seamlessly with automated platforms and standard cell health assays such as MTT, XTT, Cell Titer-Glo® and many others.’ Prof. Heiner Fiebig, founder and CEO of Oncotest said, ‘We are very pleased to be able to offer cancer cell cytotoxicity assays using Alvetex®Scaffold 96 well plates to our clients. We have looked at several different technologies and found Alvetex®Scaffold to be the simplest and most reliable solution. We particularly value the ease of use, ability to automate the entire workflow and the ability to isolate protein and RNA from the treated cells to study drug effects post-treatment. The combination of Alvetex®Scaffold, state-of-the- Oncotest will begin offering services immediately to existing clients, and will offer a new introductory screening service for companies new to 3D cell culture who want to try out 3D culture based oncology services. Financial terms were not disclosed. For more information please visit www.reinnervate.com or www.oncotest.de For further information, please contact Ashley Cooper, Chief Executive Officer +44 (0)1740 625266 info@reinnervate.com David Robinson Alto Marketing +44 (0) 1489 557672 davidr@alto- Torsten Giesemann Oncotest GmbH +49 (0) 761 5155943 torsten.giesemann@ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|